can semaglutide cause permanent gastroparesis June Blog Post: T2DM Management complicated by Ozempic & Wegovy - Gastroparesis

The trial reported weight loss for these subgroups combined, which is why the percentages match

Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist that showed up to 24.2% weight loss in phase 2 trials at 48 weeks, potentially exceeding both CagriSema and tirzepatide

Several Aetna plans have removed Zepbound from their formulary for weight management, effective July 2025

The FDA has not reviewed or approved compounded products for any use for safety, efficacy, or quality

The active peptide degrades silently

This compound increased inflammation by increasing NF-B (a master regulator of inflammation) in mice [25]